Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Revenues: 108.41M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
JAZZ Revenues Rankings
| Overall | 48th percentile | 2261 of 4432 |
| Sector | 68th percentile | 147 of 470 in Healthcare |
| Industry | 88th percentile | 15 of 132 in Biotechnology |
JAZZ Revenues Range, Past 5 Years
| Minimum | 14.26M | Jun 2007 |
| Maximum | 108.41M | Mar 2012 |
| Average | 40.08M |
About Revenues
Income that a company gains from business activities, calculated before any expenses are subtracted. Includes all sales and other increases in owner's equity.
Learn More
You may also be interested in these JAZZ related companies
JAZZ News
A Forward Look, the Year Ahead - Featured Research on Jazz Pharmaceuticals and Human Genome Sciences
May 24, 9:00AM Marketwire
May 24, 9:00AM Marketwire
$JAZZ more Buy notes out today,mid $60's PT,Use caution,still struggling w/200,mkt's pulling down the winners from 1-3/yrs gainers
about 7 days ago by HighGrowthFinancial
about 7 days ago by HighGrowthFinancial
StockTwits 50, May 21 | via @StockTwits50 http://stks.co/3uBO $PCYC CYBX $ASGN $EXPE $JAZZ
about 11 days ago by STNet
about 11 days ago by STNet
Shorted some $JAZZ @ the 200 which it can't seem to hold, trail stop a wiggle above
about 12 days ago by HighGrowthFinancial
about 12 days ago by HighGrowthFinancial
$JAZZ few buyer's stepping in here, not me, not yet anyway
about 13 days ago by HighGrowthFinancial
about 13 days ago by HighGrowthFinancial
$JAZZ still looking like distribution,all vol to the downside,-10% 5day,and now down 5% on the 3month, Needs $46.50 to get excited
about 13 days ago by HighGrowthFinancial
about 13 days ago by HighGrowthFinancial
$JAZZ recovered from past few days of selling. Looking good here. Joins the Nasdaq Biotech Index on May 21st.
about 14 days ago by abubnic
about 14 days ago by abubnic
$JAZZ as posted b4 $45 key level for tech reasons, only hurdle is Ownership here, +6,200% 3yrs can be turbulent at times.Good company.Beta
about 14 days ago by HighGrowthFinancial
about 14 days ago by HighGrowthFinancial
$JAZZ 45 level is stalling right now....could very well test the 200 day MA around 43 ish....
about 14 days ago by brentkrug
about 14 days ago by brentkrug
Auriga Reiterates a 'Buy' on Jazz Pharmaceuticals (JAZZ); Lifting Numbers on 'Beat & Raise'
May 09, 10:32AM Street Insider
May 09, 10:32AM Street Insider
Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Apr 30, 7:40PM PR Newswire
Apr 30, 7:40PM PR Newswire
Auriga Reiterates a 'Buy' on Jazz Pharmaceuticals (JAZZ) After Call With Patent Attorney
Apr 20, 12:29PM Street Insider
Apr 20, 12:29PM Street Insider
Leerink Swann Starts Jazz Pharmaceuticals (JAZZ) at Outperform; Compelling Risk/Reward
Apr 13, 7:39AM Street Insider
Apr 13, 7:39AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| JAZZ | 44.61 | -1.46 | -3.17% | 2.591B |
| JAX | 8.60 | -0.05 | -0.58% | 51.81M |
| JASO | 0.9463 | -0.03 | -3.44% | 164.53M |
| JAKK | 18.23 | +0.09 | +0.50% | 472.00M |
| IVE | 59.84 | -0.97 | -1.60% | |
| IVD | 0.5801 | +0.00 | +0.00% | 19.95M |
| IVAN | 0.76 | -0.02 | -2.56% | 268.43M |
| IVAC | 7.80 | -0.08 | -1.02% | 183.29M |
| ITW | 55.92 | -1.28 | -2.24% | 27.54B |
| ITUB | 13.95 | -0.33 | -2.31% | 65.26B |
